Abstract
Background: Arrhythmia induced by etoposide is exceedingly rare. There are only a very few individual case histories of arrhythmias during etoposide infusion, including atrial fibrillation. Objective: Through this uncommon case, we propose to study the pathophysiology, the diagnosis and the management of this entity.
Case Report: We report a case of a 57-year-old man, without cardiac history, followed for endocrine tumor of the pancreas with liver metastases who had presented atrial fibrillation (AF) after etoposide infusion.
Conclusion: It is important to consider cardiac monitoring during etoposide infusion in patients with known cardiac disease or at high risk of cardiac complications.
Keywords: Atrial fibrillation, cardiotoxicity, chemotherapy, diagnosis, etoposide, prognosis.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Targets
Current Neuropharmacology
Current Pharmaceutical Design
Current Pharmaceutical Analysis
Current Vascular Pharmacology
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Related Books
Frontiers in Drug Design and Discovery
New Findings from Natural Substances
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Medical Applications of Beta-Glucan
30